Effects of α-adrenoceptor Antagonists on ABCG2/BCRP-mediated Resistance and Transport

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 23

PMID 22355323

Citations 4

Authors

Kohji Takara

Kazuhiro Yamamoto

Mika Matsubara

Tetsuya Minegaki

Minoru Takahashi

Teruyoshi Yokoyama

Katsuhiko Okumura

Affiliations

Soon will be listed here.

Abstract

Acquired resistance of cancer cells to various chemotherapeutic agents is known as multidrug resistance, and remains a critical factor in the success of cancer treatment. It is necessary to develop the inhibitors for multidrug resistance. The aim of this study was to examine the effects of eight α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. Previously established HeLa/SN100 cells, which overexpress ABCG2/BCRP but not ABCB1/MDR1, were used. The effects of the antagonists on sensitivity to mitoxantrone and the transport activity of Hoehst33342, both substrates for ABCG2/BCRP, were evaluated using the WST-1 assay and cellular kinetics, respectively. ABCG2/BCRP mRNA expression and the cell cycle were also examined by real-time RT-PCR and flow cytometry, respectively. Sensitivity to mitoxantrone was reversed by the α-adrenoceptor antagonists in a concentration-dependent manner, although such effects were also found in the parental HeLa cells. Levels of ABCG2/BCRP mRNA expression were not influenced by the antagonists. The transport activity of Hoechst33342 was decreased by doxazosin and prazosin, but unaffected by the other antagonists. In addition, doxazosin and prazosin increased the proportion of S phase cells in the cultures treated with mitoxantrone, whereas the other α-adrenoceptor antagonists increased the percentage of cells in G(2)/M phase. These findings suggested that doxazosin and prazosin reversed resistance mainly by inhibiting ABCG2/BCRP-mediated transport, but the others affected sensitivity to mitoxantrone via a different mechanism.

Citing Articles

Identification of side population cells in human lung adenocarcinoma A549 cell line and elucidation of the underlying roles in lung cancer.

Xie T, Mo L, Li L, Mao N, Li D, Liu D Oncol Lett. 2018; 15(4):4900-4906.

PMID: 29552128 PMC: 5840558. DOI: 10.3892/ol.2018.7956.

Isolation and sequencing of swine carbonic anhydrase VI, an enzyme expressed in the swine kidney.

Nishita T, Yatsu J, Murakami M, Kamoshida S, Orito K, Ichihara N BMC Res Notes. 2014; 7:116.

PMID: 24576305 PMC: 3975938. DOI: 10.1186/1756-0500-7-116.

Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition.

Yamamoto K, Uda A, Mukai A, Yamashita K, Kume M, Makimoto H J Exp Clin Cancer Res. 2014; 32:83.

PMID: 24423131 PMC: 3874739. DOI: 10.1186/1756-9966-32-83.

Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Ciocca D, Arrigo A, Calderwood S Arch Toxicol. 2012; 87(1):19-48.

PMID: 22885793 PMC: 3905791. DOI: 10.1007/s00204-012-0918-z.

References

Cruise J, Houck K, Michalopoulos G . Induction of DNA synthesis in cultured rat hepatocytes through stimulation of alpha 1 adrenoreceptor by norepinephrine. Science. 1985; 227(4688):749-51. DOI: 10.1126/science.2982212. View

Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J . A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm. 2006; 3(1):45-54. DOI: 10.1021/mp050088t. View

Pan S, Guh J, Huang Y, Chern J, Chou J, Teng C . Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol. 2003; 169(2):724-9. DOI: 10.1097/01.ju.0000037731.83941.db. View

Kojima Y, Sasaki S, Oda N, Koshimizu T, Hayashi Y, Kiniwa M . Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate. 2009; 69(14):1521-8. DOI: 10.1002/pros.21003. View

Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K . Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004; 10(5):1691-7. DOI: 10.1158/1078-0432.ccr-0937-3. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross D . The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000; 113 ( Pt 11):2011-21. DOI: 10.1242/jcs.113.11.2011. View

POOL J, Kirby R . Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol. 2002; 33(3):407-12. DOI: 10.1023/a:1019504703485. View

Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y . Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2008; 61(1):26-33. DOI: 10.1016/j.addr.2008.07.003. View

10.

Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T . Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett. 2009; 278(1):88-96. DOI: 10.1016/j.canlet.2008.12.033. View

11.

Benning C, Kyprianou N . Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 2002; 62(2):597-602. View

12.

Siddiqui E, Shabbir M, Thompson C, Mumtaz F, Mikhailidis D . Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?. Anticancer Res. 2005; 25(6B):4281-6. View

13.

Fletcher J, Haber M, Henderson M, Norris M . ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2):147-56. DOI: 10.1038/nrc2789. View

14.

Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M . Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002; 25(6):771-8. DOI: 10.1248/bpb.25.771. View

15.

Koceva-Chyla A, Jedrzejczak M, Skierski J, Kania K, Jozwiak Z . Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis. 2005; 10(6):1497-514. DOI: 10.1007/s10495-005-1540-9. View

16.

Liao C, Guh J, Chueh S, Yu H . Anti-angiogenic effects and mechanism of prazosin. Prostate. 2011; 71(9):976-84. DOI: 10.1002/pros.21313. View

17.

Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N . Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila). 2011; 4(1):87-96. DOI: 10.1158/1940-6207.CAPR-10-0189. View

18.

Tahmatzopoulos A, Rowland R, Kyprianou N . The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother. 2004; 5(6):1279-85. PMC: 2274914. DOI: 10.1517/14656566.5.6.1279. View

19.

Zhou L, Schmidt K, Nelson F, Zelesky V, Troutman M, Feng B . The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos. 2009; 37(5):946-55. DOI: 10.1124/dmd.108.024489. View

20.

Partin J, Anglin I, Kyprianou N . Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer. 2003; 88(10):1615-21. PMC: 2377124. DOI: 10.1038/sj.bjc.6600961. View